Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 1/2017

01-02-2017 | Announcement

Message from the Editor-in-Chief regarding ethical violations

Published in: Clinical Journal of Gastroenterology | Issue 1/2017

Login to get access

Excerpt

Recently two manuscripts were submitted to the Clinical Journal of Gastroenterology that contained possible acts of plagiarism. They were brought to the attention of the editors by CrossCheck, a similarity check and plagiarism detection tool, implemented into our Editorial Manager. Both manuscripts were finally judged to be plagiarism, and rejected at the time of peer review. In both manuscripts, the first authors were also the corresponding authors and were deemed mainly responsible for plagiarism. The journal has banned them from submitting to the journal for 1–2 years, depending on the degree of plagiarism. …
Metadata
Title
Message from the Editor-in-Chief regarding ethical violations
Publication date
01-02-2017
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 1/2017
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-016-0706-z

Other articles of this Issue 1/2017

Clinical Journal of Gastroenterology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine